Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03279055 · ClinicalTrials.gov registry record · NA

Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors

A NA study of Insomnia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT03279055 is a NA study of Insomnia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03279055, a NA study of Insomnia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.

Conditions Studied

Insomnia

Interventions

  • BEHAVIORAL SHUTi

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-08-10
Est. Completion 2019-12-20
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03279055

The ClinicalTrials.gov registry entry for NCT03279055 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which SHUTi is the first listed.

NCT03279055 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03279055 about?

NCT03279055 is a clinical study titled "Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors". This research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.

What is the current status of trial NCT03279055?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2018-08-10. Estimated completion is 2019-12-20.

What conditions does trial NCT03279055 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT03279055?

The interventions under investigation include: SHUTi (BEHAVIORAL).

Who is sponsoring clinical trial NCT03279055?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03279055 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Insomnia

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.